(Q37971867)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Neutralizing antibodies and control of HIV: moves and countermoves (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Ann J Hessell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

published in

Current HIV/AIDS reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

64-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22203469%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11904-011-0105-5

19 January 2020

exact match

0 references

cites work

Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Identifying and characterizing recently transmitted viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

HIV neutralizing antibodies: clinical correlates and implications for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Transmission of HIV-1 in the face of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Fc receptor but not complement binding is important in antibody protection against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broad neutralization coverage of HIV by multiple highly potent antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Structural definition of a conserved neutralization epitope on HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Constraints on HIV-1 diversity from protein structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

HIV-1 envelope subregion length variation during disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

The role of antibodies in HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Toward an antibody-based HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

21 January 2018

Polyvalent AIDS vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Targeting early infection to prevent HIV-1 mucosal transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Induction of immunity to human immunodeficiency virus type-1 by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0105-5

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

21 January 2018

1 reference

12 December 2020

Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection.

1 reference

12 December 2020

Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

1 reference

12 December 2020

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

1 reference

12 December 2020

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

1 reference

12 December 2020